Gastric cancer,capecitabin.pembrolizumab.
Conditions
Interventions
Intervention group:.
Sponsors
Iran University of Medical Sciences
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Having stomach cancer that is resistant to first-line chemotherapy treatments Providing informed written consent to participate in the study
Exclusion criteria
Exclusion criteria: Patients’ unwillingness to continue participating in the study Death of the patient from causes other than stomach cancer before the end of the study follow-up period
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1.Quality of Life (QoL): Assessed using a validated questionnaire (e.g., EORTC QLQ-C30) at baseline and during follow-up.2.Overall Survival (OS): Time from randomization to death from any cause, measured during the study follow-up period. Timepoint: 1.Quality of Life (QoL): Assessed at baseline (before starting second-line treatment), then every 3 months during follow-up, until the end of the study.2.Overall Survival (OS): Measured from the date of randomization until death from any cause or the end of the follow-up period (up to 24 months). Method of measurement: 1.Quality of Life (QoL): Measured using the validated European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30).2.Overall Survival (OS): Measured as the time interval between randomization and death from any cause, recorded through medical records and follow-up visits. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactSara teihou jorshari
Iran University of Medical Sciences
Outcome results
None listed